Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL ER versus SOLOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL ER versus SOLOSEC.
FLAGYL ER vs SOLOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
750 mg orally once daily for 10 days for bacterial vaginosis.
2 g orally as a single dose for trichomoniasis.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic